Tanvex BioPharma Valuation
| 6541 Stock | TWD 71.60 0.40 0.56% |
At this time, the company appears to be fairly valued. Tanvex BioPharma has a current Real Value of NT$71.45 per share. The regular price of the company is NT$71.6. Our model measures the value of Tanvex BioPharma from inspecting the company fundamentals such as Current Valuation of 14.19 B, return on equity of -0.6, and Shares Owned By Insiders of 53.74 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Tanvex BioPharma's price fluctuation is very steady at this time. Calculation of the real value of Tanvex BioPharma is based on 3 months time horizon. Increasing Tanvex BioPharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tanvex stock is determined by what a typical buyer is willing to pay for full or partial control of Tanvex BioPharma. Since Tanvex BioPharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tanvex Stock. However, Tanvex BioPharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 71.6 | Real 71.45 | Hype 71.6 | Naive 65.63 |
The intrinsic value of Tanvex BioPharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tanvex BioPharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tanvex BioPharma helps investors to forecast how Tanvex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tanvex BioPharma more accurately as focusing exclusively on Tanvex BioPharma's fundamentals will not take into account other important factors: Tanvex BioPharma Total Value Analysis
Tanvex BioPharma is presently anticipated to have takeover price of 14.19 B with market capitalization of 17.11 B, debt of 0, and cash on hands of 1.65 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Tanvex BioPharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
14.19 B | 17.11 B | 0 | 1.65 B |
Tanvex BioPharma Investor Information
About 54.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 4.35. Tanvex BioPharma had not issued any dividends in recent years. The entity had 1000:333 split on the 28th of February 2023. Based on the key measurements obtained from Tanvex BioPharma's financial statements, Tanvex BioPharma is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Tanvex BioPharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tanvex BioPharma has an asset utilization ratio of 0.11 percent. This indicates that the Company is making NT$0.001147 for each dollar of assets. An increasing asset utilization means that Tanvex BioPharma is more efficient with each dollar of assets it utilizes for everyday operations.Tanvex BioPharma Ownership Allocation
Tanvex BioPharma shows a total of 352.74 Million outstanding shares. Tanvex BioPharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Tanvex BioPharma Profitability Analysis
The company reported the revenue of 5.41 M. Net Loss for the year was (1.54 B) with profit before overhead, payroll, taxes, and interest of 3.55 M.About Tanvex BioPharma Valuation
Our relative valuation model uses a comparative analysis of Tanvex BioPharma. We calculate exposure to Tanvex BioPharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tanvex BioPharma's related companies.Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. TANVEX BIOPHARMA is traded on Taiwan Stock Exchange in Taiwan.
8 Steps to conduct Tanvex BioPharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Tanvex BioPharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Tanvex BioPharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Tanvex BioPharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Tanvex BioPharma's revenue streams: Identify Tanvex BioPharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Tanvex BioPharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Tanvex BioPharma's growth potential: Evaluate Tanvex BioPharma's management, business model, and growth potential.
- Determine Tanvex BioPharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Tanvex BioPharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Tanvex Stock Analysis
When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.